

New Evidence and Novel Therapeutic Strategies in Myelofibrosis Care: Key Presentations at ASH 2023

Review this list of key presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition related to evidence-based strategies in the care of patients with myelofibrosis.



Download slidesets from “A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes”

clinicaloptions.com/MFSanDiego2023Program

Download slidesets summarizing key studies presented at ASH 2023

clinicaloptions.com/HEMEAnnual2023Program



Notable ASH 2023 Abstracts in Myelofibrosis: Oral Presentations on Sunday, December 10

Abstract	Title	Presenter	Time/Location
620	Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis	Pemmaraju	4:45 PM PT Ballroom 20CD San Diego Convention Center
621	Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis	Gill	5:00 PM PT Ballroom 20CD San Diego Convention Center
622	Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification	Tantravahi	5:15 PM PT Ballroom 20CD San Diego Convention Center
623	BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study	Lavie	5:30 PM PT Ballroom 20CD San Diego Convention Center
628	Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study	Rampal	5:15 PM PT Pacific Ballroom Salons 21-22 Marriott Marquis San Diego Marina

New Evidence and Novel Therapeutic Strategies in Myelofibrosis Care: Key Presentations at ASH 2023

Notable ASH 2023 Abstracts in Myelofibrosis: Posters

Saturday, December 9			
Abstract	Title	Presenter	Time/Location
1826	Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials	Mesa	5:30 PM - 7:30 PM PT Halls G-H San Diego Convention Center
Sunday, December 10			
Abstract	Title	Presenter	Time/Location
3182	Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naïve or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials	Mesa	6:00 PM - 8:00 PM PT Halls G-H San Diego Convention Center
3188	Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials	Gupta	
3189	Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study	Harrison	
3194	ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis	Abdelmagid	
3204	Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study	Harrison	
3207	Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis	Ajufo	
3209	A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)	Maher	
3211	A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)	Scandura	

New Evidence and Novel Therapeutic Strategies in Myelofibrosis Care: Key Presentations at ASH 2023

Notable ASH 2023 Abstracts in Myelofibrosis: Posters

Monday, December 11			
Abstract	Title	Presenter	Time/Location
4526	Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T-Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial	Jeyaraju	6:00 PM - 8:00 PM PT Halls G-H San Diego Convention Center
4554	Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies	Vachhani	
4555	Type 1/like Calr Mutation in Momelotinib-Treated Patients with Myelofibrosis Is the Most Prominent Predictor of Drug Survival and Longevity without Transplant	Tefferi	
4562	Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis: Durable Responses and Evidence of Disease Modification	Gill	
4566	Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib	Oh	
4571	Estimating Transfusion-Related Medical Costs and Associated Time Burden in Patients with Myelofibrosis: A Comparison of Momelotinib Vs Ruxolitinib Based on Simplify-1	Masarova	
4578	The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study	Duan	